MNKD clears the V9 momentum and asymmetry gates in a post-death-cross recovery with FCF-positive economics, but three consecutive earnings misses, overbought momentum, and a fresh negative news modifier temper conviction.
Thesis pillars
- Fcf Positive Despite Gaap Loss→Stable
- High Asymmetry Recovery Setup→Stable
- Consecutive Earnings Misses→Stable
- +2 more pillars — see the Why tab for full reasoning
MannKind Corporation (MNKD) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $4.21: Consecutive earnings misses (3); Concentration risk — Supplier: Amphastar (sole insulin supplier for Afrezza).
MannKind Corporation markets Afrezza inhaled insulin and manufactures Tyvaso DPI for pulmonary arterial hypertension on behalf of partner United Therapeutics, alongside the V-Go insulin patch and Furoscix infusor, following its October 2025 acquisition of scPharma. The company... Read more
Sell if holding. Multiple concerning factors at $4.21: Consecutive earnings misses (3); Concentration risk — Supplier: Amphastar (sole insulin supplier for Afrezza). Chart setup: Death cross but MACD improving, RSI 61. Score 5.8/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 29d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierAmphastar (sole insulin supplier for Afrezza)10-K Item 1: 'Currently, the only source of insulin that we have qualified for Afrezza is manufactured by Amphastar France Pharmaceuticals S.A.S. (“Amphastar”).'
- MEDIUMcounterpartyUnited Therapeutics (Tyvaso DPI commercialization)10-K Item 1A: 'A significant portion of our revenue is derived from royalties and collaboration and services revenue associated with United Therapeutics’ commercialization of Tyvaso DPI.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $4.21: Consecutive earnings misses (3); Concentration risk — Supplier: Amphastar (sole insulin supplier for Afrezza). Chart setup: Death cross but MACD improving, RSI 61. Prior stop was $3.95. Score 5.8/10, moderate confidence.
Take-profit target: $6.61 (+55.5% upside). Prior stop was $3.95. Stop-loss: $3.95.
Concentration risk — Supplier: Amphastar (sole insulin supplier for Afrezza); Consecutive earnings misses (3); Below 200-MA, MA slope -2.5%/30d (confirmed downtrend).
MannKind Corporation trades at a P/E of N/A (forward 22.2). TrendMatrix value score: 6.5/10. Verdict: Sell.
14 analysts cover MNKD with a consensus score of 4.1/5. Average price target: $8.
What does MannKind Corporation do?MannKind Corporation markets Afrezza inhaled insulin and manufactures Tyvaso DPI for pulmonary arterial hypertension on...
MannKind Corporation markets Afrezza inhaled insulin and manufactures Tyvaso DPI for pulmonary arterial hypertension on behalf of partner United Therapeutics, alongside the V-Go insulin patch and Furoscix infusor, following its October 2025 acquisition of scPharma. The company depends on a single qualified insulin supplier, Amphastar, under a €120.1 million purchase commitment, and on United Therapeutics' continued commercial prioritization of Tyvaso DPI.